治疗抵抗性 nAMD 换用 faricimab 的三年真实世界结果:133 只眼回顾性研究
Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degeneration
一项单中心回顾性研究报告了 133 只治疗抵抗性新生血管性年龄相关性黄斑变性(nAMD)眼从 aflibercept 2 mg 换用 faricimab 后的三年结果,这些眼此前即使接受 aflibercept 2 mg ≤8 周间隔治疗仍存在持续性或复发性视网膜内液和/或视网膜下液,或治疗耐久性不足。
Long-term real-world evidence on faricimab in previously treated, treatment-resistant neovascular age-related macular degeneration (nAMD) remains limited. Although pivotal trials demonstrated sustained visual outcomes and extended dosing intervals in treatment-naïve eyes, these findings may not be directly applicable to patients with chronic disease, persistent exudative activity, and a high treatment burden despite frequent anti-vascular endothelial growth factor (VEGF) therapy [1]. This study reports three-year outcomes following a switch from aflibercept 2 mg (Eylea; Bayer, Germany) to faricimab (Vabysmo; Roche, Switzerland) in treatment-resistant nAMD, extending the previously published 12- and 24-month analyses of this cohort [2, 3].
This retrospective, single-centre study was approved by the Trust clinical audit department (MEDRET/SE/2026-27/08) and followed the Declaration of Helsinki. It included 133 eyes of 107 patients with persistent or recurrent intraretinal fluid (IRF) and/or subretinal fluid (SRF), or inadequate treatment durability, despite aflibercept 2 mg ≤8-week intervals. All eyes received four monthly faricimab loading injections followed by an individualised treat-and-extend regimen, with a minimum follow-up of 30 months after switching; mean follow-up was 38.8 (2.5) months (range 30–41). At baseline, mean patient age was 82.8 (7.4) years, and eyes had received a mean of 7.6 (1.7) aflibercept 2 mg injections during the preceding year.
Mean best-recorded visual acuity (BRVA) was 67.6 (13.1) ETDRS letters at baseline and 65.0 (19.1) at year 3 [mean change −2.6 letters; (95%CI, 61.8-68.3 letters; p = 0.648)]. Mean central subfield thickness (CST) decreased from 304.7 (90.4) µm to 219.5 (50.9) µm [mean change −85.2 µm; (95%CI, 210.8-228.2 µm; p < 0.001)].
Complete resolution of both IRF and SRF increased from 10.5% at baseline to 55.6% at year 3. SRF prevalence declined from 79.7% to 30.8% (p < 0.001), while IRF prevalence decreased from 32.3% to 21.1% (p = 0.022) (Table 1).
Mean treatment interval increased from 5.8 (1.4) weeks before switching to 11.5 (6.4) weeks at year 3 (p < 0.001). At final follow-up, 45.9% of eyes achieved treatment intervals of at least 12 weeks, including 18.8% treated at intervals of at least 16 weeks and 3.0% at intervals of at least 20 weeks (Fig. 1). Eyes received a cumulative mean of 20.3 (4.4) faricimab injections, and three eyes were switched to aflibercept 8 mg for insufficient response. These findings accord with emerging long-term real-world evidence in previously treated eyes [4, 5].
Bars show the percentage of eyes (n = 133) within each treatment-interval category at baseline, after the loading phase, and at years 1, 2, and 3.
Across 2696 faricimab injections, four ocular adverse events occurred (0.15% of injections; four of 133 eyes, 3.0%): anterior chamber inflammation, retinal detachment, retinal tear requiring retinopexy, and haemorrhage requiring displacement. No endophthalmitis, retinal vasculitis, retinal artery occlusion, or faricimab-attributable systemic event occurred.
These findings suggest that switching to faricimab may provide sustained anatomical improvement, treatment-interval extension, and preservation of visual acuity over three years in treatment-resistant nAMD. Despite the retrospective, non-comparative design, and physician-directed interval adjustment, which limit causal interpretation, to our knowledge, this is the longest real-world follow-up of faricimab reported in this population.
Data availability
The datasets generated and analysed during the current study are not publicly available because they contain information that could compromise the privacy of research participants but are available from the corresponding author on reasonable request.
References
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914–26.
Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38:3059–64.
Ahmed E, Goodchild C, Bisoukis A, Salvatore S. Two-year real-world outcomes of faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2026;20:596406.
Saito M, Imaizumi K. Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration. Sci Rep. 2025;15:30699.
Mohan N, Schulgit MJ, Bellanda V, Barbosa GCS, Szigiato A, Talcott KE, et al. Long-term outcomes of faricimab in previously treated neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2026;57:220–6.
Acknowledgements
The authors thank the intravitreal injection service, the clinical and imaging teams at Bristol Eye Hospital for their support.
Funding
No funding was received for the conduct of this study. Open access publication was funded by a grant received from Roche, which had no involvement in the research or preparation of the manuscript.
Author information
Authors and Affiliations
Department of Ophthalmology, Bristol Eye Hospital, Bristol NHS Foundation Trust, Bristol, UK
Pierluigi Daniele, Eslam Ahmed, Anastasios Bisoukis & Serena Salvatore
Department of Ophthalmology, University La Sapienza of Rome, Rome, Italy
Pierluigi Daniele
Department of Ophthalmology, Hermitage Medical Clinic, Dublin, Ireland
Christine Goodchild
Department of Ophthalmology, King’s College Hospital NHS Foundation Trust, London, UK
Anastasios Bisoukis
Authors
- Pierluigi Daniele
- Christine Goodchild
- Eslam Ahmed
- Anastasios Bisoukis
- Serena Salvatore
Contributions
SS conceived and supervised the study and is responsible for the overall content as guarantor. PD, AB and EA acquired and curated the clinical data. CG contributed to study design, statistical analysis and data interpretation. PD drafted the manuscript. CG, EA, AB, and SS revised it critically for important intellectual content. All authors approved the final version and agree to be accountable for all aspects of the work.
Corresponding author
Correspondence to Serena Salvatore.
Ethics declarations
Competing interests
SS is an advisory board member for Advanz Pharma, Bayer, Alimera Sciences and Roche; has received speaker honoraria from AbbVie, Alimera Sciences, Bayer, Roche and Sandoz; and has received travel support from Alimera Sciences, Bayer and Roche. PD, EA and AB declare no competing interests. CG received travel support from Alimera Sciences, AbbVie, Santen and Roche, and speaker honoraria from Roche and Scope.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Daniele, P., Goodchild, C., Ahmed, E. et al. Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degeneration. Eye (2026). https://doi.org/10.1038/s41433-026-04916-0
Received: 15 August 2026
Revised: 26 August 2026
Accepted: 14 September 2026
Published: 02 October 2026
Version of record: 02 October 2026
DOI: https://doi.org/10.1038/s41433-026-04916-0
来源:Nature 健康护理主题 · nature.com